© 2025 HSP News Service, L.L.C.
In a recent study, use of solifenacin was associated with a statistically significant improvement in continence in patients who underwent robotic-assisted radical prostatectomy, although no statistically significant difference in the time to return to continence. The results of this study,...
In a phase II study reported in the Journal of Clinical Oncology, Taplin et al found that the addition of neoadjuvant abiraterone acetate (Zytiga) to the luteinizing hormone–releasing hormone (LHRH) agonist leuprolide acetate resulted in greater suppression of intraprostatic androgens in...
The American Society of Clinical Oncology (ASCO) today issued an endorsement of the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on the use of adjuvant and salvage radiotherapy after prostatectomy, which was based on a systematic review of medical...
The phase III ALSYMPCA trial showed that radium-223 (Xofigo) increased overall survival vs placebo patients with castration-resistant prostate cancer and symptomatic bone metastases. In a prespecified subgroup analysis reported in The Lancet Oncology, Hoskin et al found that overall survival...
While early treatment of prostate cancer recurrence after a radical prostatectomy based on detectable or rising prostate-specific antigen (PSA) levels may reduce the risk of disease metastasis, even without salvage treatment, many patients will die of other causes before metastatic disease...
Prostate cancer survivors with higher levels of total cholesterol and triglycerides had an increased risk for disease recurrence, according to a study by Allott et al. The study findings, coupled with evidence that statin use is associated with reduced recurrence risk, suggest that lipid levels...
In an analysis of outcomes in patients with node-positive prostate cancer reported in the Journal of Clinical Oncology, Abdollah et al found that adjuvant radiotherapy is associated with a survival benefit in patients with low-volume nodal disease in the setting of intermediate- to high-grade...
Abiraterone acetate (Zytiga) is approved for use in combination with prednisone in the treatment of metastatic castration-resistant prostate cancer. As reported by Sternberg et al in The Lancet Oncology, results of an open-label, early-access protocol trial initiated prior to approval indicated no...
The androgen receptor isoform encoded by splice variant 7 is constitutively active as a transcription factor, despite lacking the ligand-binding domain that is the target of enzalutamide (Xtandi) and abiraterone (Zytiga). In a study reported in The New England Journal of Medicine, Antonarakis et al ...
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker adjacent to the KLK3 gene that can predict which prostate cancer patients with a Gleason score of 7 will have a more aggressive form of cancer. The findings by He et al, published in Clinical Cancer...
Men with higher estradiol-to-testosterone ratios had a substantially reduced risk of aggressive prostate cancer, whereas men with higher ratios of 2-hydroxyestrone to 16α-hydroxyestrone had an increased risk of such cancer, according to the study findings presented by Black et al in Cancer...
A final analysis of the phase III COU-AA-302 trial showed that abiraterone acetate (Zytiga) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer. The study,...
A temporary rise in prostate-specific antigen (PSA) scores after radiotherapy may have an association with outcomes in patients with prostate cancer, according to the study findings presented by Naghavi et al in the International Journal of Clinical Oncology. Experiencing a PSA bounce was...
In a phase II expansion study reported in the Journal of Clinical Oncology, Smith et al found that the multikinase inhibitor cabozantinib (Cometriq) showed activity in previously treated metastatic castration-resistant prostate cancer. Cabozantinib targets include VEGFR2 and MET kinases. Study...
In the introduction to a cohort study reported in JAMA Surgery, Parsons et al stated “Surgical innovations disseminate in the absence of coordinated systems to ensure their safe integration into clinical practice, potentially exposing patients to increased risk for medical error.” Their ...
In a prospective cohort study in the population of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Zhou et al found that frontal plus moderate vertex baldness at age 45 is associated with increased risk of aggressive prostate cancer. The findings were reported in the...
Prostate cancer patients who receive high-dose radiation therapy followed by a longer period of androgen-deprivation therapy have higher 5-year biochemical disease–free survival and overall survival rates compared to patients who receive high-dose radiation therapy and a shorter duration of...
The UK phase III ProtecT trial is comparing the effectiveness of active monitoring, radical prostatectomy, and radiotherapy in men with localized prostate cancer. Lane et al have provided baseline results of the trial in an article in The Lancet Oncology. Study Details In the trial, men aged 50...
Patients with high-risk prostate cancer who received radiation therapy and an 18-month course of androgen-deprivation therapy recovered a normal testosterone level in a shorter amount of time compared to those who received a 36-month course of androgen-deprivation therapy. The shorter course of...
The U.S. Food and Drug Administration (FDA) has approved a new indication for the use of enzalutamide (Xtandi) capsules to treat patients with metastatic castration-resistant prostate cancer. The new indication is for men with metastatic castration-resistant prostate cancer who have not received...
The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...
Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the journal Genome Biology. Because a tumor’s RNA shows the real-time changes a treatment is causing, the authors believe that this could be a...
A new study reveals that the United States has experienced widespread adoption of robot-assisted prostatectomy to treat prostate cancer in recent years. The findings, reported by Chang et al in BJU International, also showed that although such surgeries are more expensive than traditional...
In a phase III Australian/New Zealand trial (TROG 03.04 RADAR) reported in The Lancet Oncology, Denham et al found no differences in prostate cancer–specific or all-cause mortality with intermediate-term androgen suppression and radiotherapy or short-term suppression plus radiotherapy with or ...
Transrectal ultrasound guided biopsy is the standard for detecting prostate cancer, but international reports have suggested that the risks associated with the procedure are increasing. In a new nationwide population-based study reported in The Journal of Urology, Swedish researchers found that 6%...
The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), reported by Schröder et al in The Lancet, showed that prostate-specific antigen (PSA) screening in men aged 55 to 69 years is associated with a 21% reduction in risk of prostate cancer mortality...
Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study by Gritz et al published in Cancer Epidemiology, Biomarkers & Prevention. The Prostate Cancer Prevention Trial, ...
In the phase III international AFFIRM trial, enzalutamide (Xtandi) was shown to improve overall survival vs placebo in men with metastatic castration-resistant prostate cancer after progression on docetaxel. In an analysis of secondary endpoints reported in The Lancet Oncology, Fizazi et al found...
Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. In a recent article in the Archives of Pathology & Laboratory Medicine, a...
Primary androgen-deprivation therapy has been widely used in localized prostate cancer, despite absence of definitive evidence of benefit in early-stage disease. In a large population-based cohort study reported in JAMA Internal Medicine, Lu-Yao et al found that primary androgen-deprivation therapy ...
In a population-based cohort study reported in the Journal of Clinical Oncology, Prasad et al found that men with depressive disorder prior to prostate cancer diagnosis were significantly less likely to undergo definitive therapy and had worse overall survival across all risk strata compared with...
Most older men with low-risk prostate cancer receive upfront treatment, despite absence of clear survival benefit and potential for morbidity. In a retrospective cohort study reported in JAMA Internal Medicine, Hoffman et al found that use of observation as management in this setting varied widely...
Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital. The study by Diaz et al, published in European Urology, also suggested that traditional methods of measuring the...
ODM-201 is a novel androgen receptor inhibitor—structurally distinct from enzalutamide (Xtandi)—that acts via high-affinity binding to the androgen receptor and inhibition of receptor nuclear translocation. In the phase I/II ARADES trial reported in The Lancet Oncology, Fizazi et al...
An analysis of data from the Health Professionals Follow-Up Study reported by Siddiqui et al in the Journal of Clinical Oncology indicates that vasectomy is associated with a modestly but significantly increased risk of high-grade and lethal prostate cancer. The study involved data from 49,405...
Key genetic variants may affect how cancer patients respond to radiation treatments, according to a study recently published in Nature Genetics. The research team, which included researchers at the Icahn School of Medicine at Mount Sinai, found that variations in the TANC1 gene are associated with...
Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700), an investigational oral, nonsteroidal, selective inhibitor of 17,20-lyase, for prostate cancer. The decision follows the results of two phase III...
The androgen receptor inhibitor enzalutamide (Xtandi) has been shown to prolong survival in men with metastatic castration-resistant prostate cancer with progressive disease after chemotherapy. In the phase III PREVAIL trial reported in The New England Journal of Medicine, Beer et al found that...
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...
Men with prostate cancer generally have an excellent prognosis, but questions remain about the risk of second primary malignancies after initial therapy for localized disease. According to a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 5034), although the overall risk of ...
According to a new study by researchers at the University of California, Los Angeles, selection of men for active surveillance for prostate cancer should be based not on conventional biopsy, but on a new, imaging-guided targeted prostate biopsy. The new biopsy method is now a routine part of the...
In a phase III trial (CA184-043) reported in The Lancet Oncology, Kwon et al assessed the effects of adding ipilimumab (Yervoy) after radiotherapy in patients with metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy. The investigators found no improvement...
In an article in The Lancet Oncology, Sartor et al report symptomatic skeletal event outcomes in the phase III ALSYMPCA trial, which was the study supporting the May 2013 approval of radium-233 dichloride (Xofigo) in patients with castration-resistant prostate cancer and bone metastases. They found ...
According to the results from three studies published in European Urology, the 17-gene Oncotype DX Genomic Prostate Score is a significant predictor of disease aggressiveness at the time of diagnosis before intervention with radiation or surgery. The test provides more precise and individualized...
According to a large, population-based observational study of men who had a prostate-specific antigen (PSA)-only based relapse after prostate surgery or radiation therapy, delaying androgen deprivation therapy until the onset of symptoms or appearance of cancer on a scan does not substantially...
In a study reported in British Journal of Cancer, Shaw et al assessed the accuracy of several reported criteria for identifying insignificant prostate cancer for active surveillance in a population of unscreened men. None of the examined tools provided sufficient discrimination of insignificant...
Men who begin taking statins after prostate cancer surgery are less likely to have a recurrence of their cancer, according to a retrospective analysis led by researchers at Duke Medicine. The study by Allott et al was published in BJU International. “Our findings suggest that beginning...
A study investigating vitamin D status and prostate cancer diagnosis in high-risk men has found an association between vitamin D deficiency and aggressive prostate cancer. The study enrolled 667 men, ages 40 to 79 years, who were undergoing their first prostate biopsy following an abnormal...
Active prostate cancer cells in the bone environment can disrupt the bone remodeling process, promoting a “vicious cycle” of extensive bone destruction and formation that yields nutrients allowing prostate cancer cells to grow. To simulate this complex biologic process, researchers have ...
OncoGenex Pharmaceuticals, Inc, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen (OGX-011) when administered in combination with cabazitaxel (Jevtana Kit)/prednisone for the treatment of men with metastatic...